Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.31 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.31 |
| ▸ | ULK3 | Q6PHR2 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24944207 | 1.00 | LRRK2 (0.37) | LRRK2IKBKETBK1ULK3MKNK2 | |
| SCHEMBL30205523 | 1.00 | LRRK2 (0.37) | LRRK2IKBKETBK1ULK3MKNK2 | |
| SCHEMBL24944208 | 1.00 | LRRK2 (0.37) | LRRK2IKBKETBK1ULK3MKNK2 | |
| SCHEMBL30205542 | 0.94 | LRRK2 (0.38) | LRRK2IKBKETBK1ULK3MKNK2 | |
| SCHEMBL24944216 | 0.94 | LRRK2 (0.38) | LRRK2IKBKETBK1ULK3MKNK2 | |
| SCHEMBL29173311 | 0.90 | LRRK2 (0.37) | LRRK2IKBKETBK1ULK3MKNK2 | |
| SCHEMBL24944553 | 0.88 | LRRK2 (0.42) | LRRK2IKBKETBK1ULK3MKNK2 | |
| SCHEMBL24944203 | 0.87 | LRRK2 (0.34) | LRRK2SYK | |
| SCHEMBL30205610 | 0.87 | LRRK2 (0.34) | LRRK2SYK | |
| SCHEMBL29173323 | 0.87 | LRRK2 (0.34) | LRRK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | claimed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | LRRK2 3283/4885IKBKE 223/4885TBK1 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.